Peter S. Ganly
Christchurch, CAN, New Zealand
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: April 28, 2025
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Journal: The New England journal of medicine
Published: June 03, 2024
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Journal: Future oncology (London, England)
Published: December 13, 2023
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 28, 2023
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Journal: The New England journal of medicine
Published: December 13, 2022
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 17, 2022
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2021
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
Journal: European journal of haematology
Published: February 12, 2020
Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre.
Journal: Internal medicine journal
Published: May 20, 2018
Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study.
Journal: Annals of hematology
Published: March 14, 2018
Last Updated: 09/26/2026